Year |
Citation |
Score |
2013 |
Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Research. 73: 1190-200. PMID 23204226 DOI: 10.1158/0008-5472.Can-12-2440 |
0.346 |
|
2012 |
Williams K, Ghosh R, Giridhar PV, Gu G, Case T, Belcher SM, Kasper S. Inhibition of stathmin1 accelerates the metastatic process. Cancer Research. 72: 5407-17. PMID 22915755 DOI: 10.1158/0008-5472.Can-12-1158 |
0.624 |
|
2012 |
Ghosh R, Narasanna A, Chakrabarty A, Engelman JA, Arteaga CL. Abstract 3: HER2 gene-amplified human breast cancer cells harboring a gatekeeper T768M mutation in HER2 overexpress EGFR ligands and are sensitive to dual therapeutic blockade of EGFR and HER2 Cancer Research. 72: 3-3. DOI: 10.1158/1538-7445.Am2012-3 |
0.355 |
|
2011 |
Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Research. 71: 1871-82. PMID 21324925 DOI: 10.1158/0008-5472.Can-10-1872 |
0.359 |
|
2009 |
Rexer BN, Ghosh R, Arteaga CL. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4518-20. PMID 19584146 DOI: 10.1158/1078-0432.Ccr-09-0872 |
0.374 |
|
2009 |
Ghosh R, Narasanna A, Gonazalez-Angulo A, Mills G, Arteaga C. Differential Signaling by ErbB Receptor (HER) Dimers: Implications for Response to Anti-HER2 Therapies in Breast Cancer. Cancer Research. 69: 705-705. DOI: 10.1158/0008-5472.Sabcs-09-705 |
0.343 |
|
2007 |
Tillman JE, Yuan J, Gu G, Fazli L, Ghosh R, Flynt AS, Gleave M, Rennie PS, Kasper S. DJ-1 binds androgen receptor directly and mediates its activity in hormonally treated prostate cancer cells. Cancer Research. 67: 4630-7. PMID 17510388 DOI: 10.1158/0008-5472.Can-06-4556 |
0.426 |
|
2007 |
Ghosh R, Gu G, Tillman E, Yuan J, Wang Y, Fazli L, Rennie PS, Kasper S. Increased expression and differential phosphorylation of stathmin may promote prostate cancer progression. The Prostate. 67: 1038-52. PMID 17455228 DOI: 10.1002/Pros.20601 |
0.71 |
|
Show low-probability matches. |